A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

Schmitz, Susanne; Adams, Róisín; Walsh, Cathal; Barry, Michael; FitzGerald, Oliver

doi:10.1136/annrheumdis-2011-200228

Cited by 62 publications

(60 citation statements)

References 42 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with a traditional metaanalysis, the Bayesian network metaanalysis permits the simultaneous comparison of all treatment options [30]. In comparison with individual studies, network meta-analysis provides more accurate data by increasing the statistical power and resolution through pooling of the results of independent analyses.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis

Lee

Bae

2016

Z Rheumatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis

Lee

Bae

2016

Z Rheumatol

View full text Add to dashboard Cite

show abstract

“…One recent MTC only considered anti-TNFs and excluded other biologics. 50 To the extent that the other biologic agents are equivalent or superior to the anti-TNFs, their exclusion risks giving clinicians the wrong impression of the best biologic agents.…”

Section: Were All Potential Treatment Options Considered?mentioning

confidence: 99%

How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis

Mills¹,

Ioannidis²,

Thorlund³

et al. 2012

JAMA

340

186

View full text Add to dashboard Cite

“…Важнейшим фактором прогресса фармакотерапии РА стало широкое внедрение генно-инженерных биологи-ческих препаратов (ГИБП). Эффективность комбиниро-ванной терапии РА метотрексатом (МТ) и ГИБП проде-монстрирована в серии рандомизированных плацебоконт-ролируемых (РПКИ) [6][7][8][9][10][11] и наблюдательных исследова-ний [12].…”

unclassified

Adalimumab Discontinuation in Patients With Rheumatoid Arthritis After Achieving Sustained Remission

Демидова¹,

Галушко²,

Глухова³

et al. 2018

rsp

View full text Add to dashboard Cite

Objective: to assess whether adalimumab (AD) can be gradually discontinued during continuous methotrexate (MTX) use in patients with early rheumatoid arthritis (ERA).Subjects and methods. Within the REMARCA (the Russian study of methotrexate and biological agents in early active arthritis) study, the investigators examined 20 patients (17 women and 3 men; median age, 51 [41.5; 56] years) with ERA (disease duration, 10 [5.5; 20] months; DAS28, 5.17 [4.37; 6.51]; 85% of the patients were seropositive for rheumatoid factor and 85% for anti-cyclic citrullinated peptide antibodies.Results and discussion. All the patients received subcutaneous MTX 25 mg/week. Twelve weeks after beginning therapy with MTX, due to its inefficiency, ADA was added according to the standard scheme. At week 24, the median DAS28 was 3.0 [1.65; 3.73]; 85% of the patients achieved remission or low disease activity. After 3 months of ADA therapy, high or moderate disease activity remained in 3 (15%) patients; median DAS28 was 4.4 [4.3; 6.1]; the drug was discontinued in them due to ineffective therapy. After 12-month follow-up, low DAS28 scores were observed in 5 (29.4%), DAS28 remission was in 12 (70.6%) of the 17 patients who continued ADA treatment; after 24 months, all the 17 patients were noted to have remission. After achieving sustained remission (≥ 6-month duration during ADA therapy), there was a carefully controlled reduction (titration) in the dose of ADA with its complete discontinuation, by maintaining remission at 36-month follow-up; the median DAS28 was 1.6 [1.4; 2.2]. During ADA treatment, one female patient developed pustular psoriasis and therefore the drug was discontinued at 24-month follow-up during the period of sustained remission. Other serious adverse events and tuberculosis cases were not recorded.Conclusion. Thus, the results of the study are indicative of the high clinical efficiency of the therapy. After ADA discontinuation, sustained remission can be maintained in patients with ERA and if they took biological agents early.

show abstract

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

Abstract: There are differences in efficacy among the TNFα antagonists. In a MTC, a continuous outcome measure has more strength to detect such differences than a binomial outcome measure because of its enhanced sensitivity to change.

Cited by 62 publications

References 42 publications

Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis

Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis

How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis

Adalimumab Discontinuation in Patients With Rheumatoid Arthritis After Achieving Sustained Remission

Contact Info

Product

Resources

About